People with hepatitis-C and those who carry the virus without even realizing it -- you have a reason to celebrate this weekend.
Hepatitis-C is a contagious virus that attacks the liver and can be found in acute or chronic forms. In nearly all instances, acute cases of hepatitis-C lead to a chronic form of the condition, which can cause cirrhosis of the liver and possibly even liver cancer. According to the Centers for Disease Control and Prevention, nearly 3.2 million people in the U.S. (about 1% of the population) are estimated to have a chronic version of the hepatitis-C virus, which is known as one of the silent killers because many of its symptoms go undetected. To put things mildly, it's a serious disease currently commanding a lot of attention from researchers.
That attention manifested itself into the approval by the Food and Drug Administration of Abbott Laboratories' (NYSE:ABT) first-ever hepatitis-C genotyping test on Thursday. Known as the Realtime HCV Genotype II, this fully automated test is capable of examining patients' blood to determine which specific genotype of the HCV virus is present out of the 11 known subtypes. Since different medications work better on certain genotypes, Abbott's Realtime HCV Genotype II test is going to revolutionize the speed of, and personalization, of hepatitis-C care.
Abbott's perfect timing
This approval from Abbott also comes on the heels of some fantastic new opportunities with regard to how hepatitis-C patients are treated.
One of today's FDA-approved treatments is Vertex Pharmaceuticals' (NASDAQ:VRTX) Incivek, which is an oral medication administered with ribavirin and a type of interferon called peginterferon alfa. While relatively effective, interferon can cause lingering flu-like symptoms in patients for up to 48 weeks, which can make the side-effects of the medication as unpleasant as the chronic HCV disease is itself. However, new drugs are currently in the works which could change all that.
I've been stating for months that Gilead's sofosbuvir has blockbuster potential written all over it. In its four late-stage clinical trials, sofosbuvir performed considerably better than the placebo in every instance. Delivering an impressive sustained viral response (SVR) of 90% in genotype 1 patients, the drug, when combined with a ribavirin, was also very effective at knocking out detectable levels of the virus in genotype 2 and 3 patients after a 12-week treatment course. Currently under review by the FDA, sofosbuvir may find dual success as a stand-alone compound and as a combination therapy.
AbbVie's hepatitis-C drug combination could be as equally exciting, with the combo producing a 97% SVR in mid-stage trials, and with it receiving the relatively new breakthrough therapy designation from the FDA in May. If AbbVie's success continues over to phase 3 trials, then, with the breakthrough therapy designation already attached, it should sail right through to an expected approval.
However, not all drugmakers have been so lucky. Bristol-Myers Squibb (NYSE:BMY), for example, shelled out $2.5 billion to purchase Inhibitex early last year, only to have its lead hepatitis-C candidate, later renamed BMS-986094, cause the death of a patient in trials and get completely scrapped, resulting in a $1.8 billion writedown.
This is a reason to celebrate
Overall, though, those with hepatitis-C and those who carry the highly mutable virus and who aren't aware of it could be on the precipice of a big shift in the quality and type of care they receive. With Abbott's test now approved, we have the personalization required to treat hepatitis-C patients; it should be only a matter of months before we have two potential blockbusters from Gilead and AbbVie dueling it out to improve patient quality of life.
Editor's note: A previous version of this article incorrectly stated that Incivek is administered through an IV and did not state that ribavirin is also part of the treatment. The Fool regrets the error.
Fool contributor Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.
The Motley Fool recommends Gilead Sciences and Vertex Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.